Illumina’s acquisition of cancer test developer Grail has also faced heavy scrutiny from antitrust regulators in the U.S. and European Union.
You are here: Home / SEC investigating Illumina over acquisition of cancer test developer Grail
Market News and Views
Illumina’s acquisition of cancer test developer Grail has also faced heavy scrutiny from antitrust regulators in the U.S. and European Union.